DOI QR코드

DOI QR Code

Triple Negative Status is a Poor Prognostic Indicator in Chinese Women with Breast Cancer: a Ten Year Review

  • Ma, K.K. (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Chau, Wai Wang (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Wong, Connie H.N. (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Wong, Kerry (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Fung, Nicholas (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Lee, J.T. Andrea (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Choi, L.Y. Catherine (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Suen, Dacita T.K. (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital) ;
  • Kwong, Ava (Division of Breast Surgery, Department of Surgery, Queen Mary and Tung Wah Hospital)
  • 발행 : 2012.05.30

초록

Background: Ethnic variation in tumor characteristics and clinical presentation of breast cancer is increasingly being emphasized. We studied the tumor characteristics and factors which may influence the presentation and prognosis of triple negative breast cancers (TNC) in a cohort of Chinese women. Methods: A prospective cohort of 1800 Chinese women with breast cancer was recruited in a tertiary referral unit in Hong Kong between 1995 and 2006 and was followed up with a median duration of 7.2 years. Of the total, 216 (12.0%) had TNC and 1584 (88.0%) had non-TNC. Their clinicopathological variables, epidemiological variables and clinical outcomes were evaluated. Results: Patients with TNC had similar age of presentation as those with non-TNC, while presenting at earlier stages (82.4% were stage 1-2, compared to 78.4% in non-TNC, p=0.035). They were likely to be associated with grade 3 cancer (Hazard Ratio(HR)=5.8, p<0.001). TNC showed higher chance of visceral relapse (HR=2.69, p<0.001), liver metastasis (HR=1.7, p=0.003) and brain metastasis (HR=1.8, p=0.003). Compared with non-TNC group, TNC had similar 10-year disease-free survival (82% vs 84%, p=0.148), overall survival (78% vs 79%, p=0.238) and breast cancer-specific mortality (18% vs 16%, p=0.095). However, TNC showed poorer 10-year stage 3 and 4 specific survival (stage 3: 53% vs. 67%, p=0.010; stage 4: 0% vs. 40%, p=0.035). Conclusions: Chinese women with triple negative breast cancer do not have less aggressive biological behavior compared to the West and presentation at a later stage results in worse prognosis compared with those with non triple negative breast cancer.

키워드

참고문헌

  1. American Joint Committee on Cancer. http://www.cancerstaging.org.
  2. Banerjee S, Reis-Filho JS, Ashley S, et al (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clinical Pathology, 59, 729-35. https://doi.org/10.1136/jcp.2005.033043
  3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109, 1721-8. https://doi.org/10.1002/cncr.22618
  4. Bloom HJ, Richardson WW (1957). Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer, 11, 359-77. https://doi.org/10.1038/bjc.1957.43
  5. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
  6. Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76. https://doi.org/10.1158/1078-0432.CCR-07-1658
  7. Dent R, Hanna WM, Trudeau M, et al (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat, 115, 423-8. https://doi.org/10.1007/s10549-008-0086-2
  8. Elias AD (2010). Triple-negative breast cancer: a short review. Am J Clinical Oncol, 33, 637-45. https://doi.org/10.1097/COC.0b013e3181b8afcf
  9. Fleming ID (2001). AJCC/TNM cancer staging, present and future. J Surg Oncol, 77, 233-6. https://doi.org/10.1002/jso.1101
  10. Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27. https://doi.org/10.1093/annonc/mdp492
  11. Haffty BG, Yang Q, Reiss M, et al (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7 https://doi.org/10.1200/JCO.2006.06.5664
  12. Kurebayashi J, Moriya T, Ishida T, et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast, 16, 72-7. https://doi.org/10.1016/j.breast.2007.07.017
  13. Kusinska R, Potemski P, Jesionek-Kupnicka D, Kordek R (2005). Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. Polish J Pathol, 56, 107-10.
  14. Kwan ML, Kushi LH, Weltzien E, et al (2009). Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res, 11, 31.
  15. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al (2011). Triple-negative breast cancer in hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer, 117, 3658-69. https://doi.org/10.1002/cncr.25961
  16. Lee JA, Kim KI, Bae JW, et al (2010). Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat, 123, 177-87. https://doi.org/10.1007/s10549-010-0998-5
  17. Lin C, Chien SY, Chen LS, et al (2009a). Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer, 9, 192. https://doi.org/10.1186/1471-2407-9-192
  18. Lin Y, Yin W, Yan T, et al (2009b). Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer, 9, 342. https://doi.org/10.1186/1471-2407-9-342
  19. Lund MJ, Trivers KF, Porter PL, et al (2009). Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research & Treatment, 113, 357-70. https://doi.org/10.1007/s10549-008-9926-3
  20. Millikan RC, Newman B, Tse CK, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39. https://doi.org/10.1007/s10549-007-9632-6
  21. O'Shaughnessy J, Osborne C, Pippen JE, et al (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England J Med, 364, 205-14. https://doi.org/10.1056/NEJMoa1011418
  22. Plummer R (2011). Poly (ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Research, 13, 218. https://doi.org/10.1186/bcr2877
  23. Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32. https://doi.org/10.1002/cncr.22381
  24. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al (2006). Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res, 12, 1533-9. https://doi.org/10.1158/1078-0432.CCR-05-2281
  25. Saip P, Cicin I, Eralp Y, et al (2009). Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol, 93, 243-51. https://doi.org/10.1007/s11060-008-9769-0
  26. Tan DS, Marchio C, Jones RL, et al (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 111, 27-44. https://doi.org/10.1007/s10549-007-9756-8
  27. Thike AA, Iqbal J, Cheok PY, et al (2010). Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surgical Pathol, 34, 956-64. https://doi.org/10.1097/PAS.0b013e3181e02f45
  28. Tischkowitz M, Brunet JS, Begin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134. https://doi.org/10.1186/1471-2407-7-134
  29. Yao-lung K, Dar-ren C, Tsai-wang C (2011). Clinicopathological features of triple-negative breast cancer in Taiwanese women. Int J Clinical Oncol, 16, 500-5. https://doi.org/10.1007/s10147-011-0211-9
  30. Yin WJ, Lu JS, Di GH, et al (2009). Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat, 115, 325-33. https://doi.org/10.1007/s10549-008-0096-0

피인용 문헌

  1. Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells vol.30, pp.7, 2013, https://doi.org/10.1007/s10585-013-9585-6
  2. There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population vol.8, pp.3, 2013, https://doi.org/10.1371/journal.pone.0060195
  3. Effect of Lymphangiogenesis and Lymphovascular Invasion on the Survival Pattern of Breast Cancer Patients vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6287
  4. Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7839
  5. Outcomes of Triple-Negative Versus Non-Triple-Negative Breast Cancers Managed with Breast-Conserving Therapy vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2577
  6. High Levels of BCOX1 Expression Are Associated with Poor Prognosis in Patients with Invasive Ductal Carcinomas of the Breast vol.9, pp.1, 2014, https://doi.org/10.1371/journal.pone.0086952